PSI模型外部验证:预测NSCLC放疗中肿瘤体积退缩
本研究在71例接受根治性放疗(55 Gy/20次)的非小细胞肺癌患者中外部验证增殖饱和指数(PSI)模型。利用CBCT 1-3、1-4、1-5的肿瘤体积动态预测最终CBCT(CBCT6)的体积,预测与实测体积高度一致(R²最高0.94,PCC最高0.97),识别不良反应者(TVR≤10%)的敏感度77.7%、特异度73.6%、阴性预测值90.7%。
要点
- PSI模型外部验证可重复且稳健地预测NSCLC根治性放疗中肿瘤体积退缩。
- 输入数据越多预测越准:R²从0.81(3次)升至0.94(5次),PCC从0.90升至0.97。
- 识别不良反应者(TVR≤10%)敏感度77.7%、特异度73.6%、阴性预测值90.7%。
核心结论
- PSI模型在独立外部队列中可重复且稳健地预测接受根治性放疗的非小细胞肺癌患者的肿瘤体积退缩。
研究设计与样本
- 外部验证研究,纳入71例仅接受根治性放疗(55 Gy/20次)的非小细胞肺癌患者。
- 从第1、2、3天及之后每周共6次锥形束CT(CBCT)提取肿瘤体积测量值。
- 使用CBCT 1-3、1-4、1-5记录的肿瘤体积动态预测最终CBCT(CBCT6)时的肿瘤体积退缩。
主要发现
- 预测体积与实测体积高度一致,且随输入数据增加而改善:R²从0.81(3次输入)升至0.94(5次输入),PCC从0.90升至0.97。
- 使用放疗约第10天(CBCT4)的数据预测时,R²=0.91,PCC=0.95。
- 模型识别不良反应者(TVR≤10%)的敏感度为77.7%、特异度为73.6%、阴性预测值为90.7%。
- 敏感性分析显示参数变化±20%以内时模型保持稳定。
关键数值与推荐
- 根治性放疗方案为55 Gy/20次。
- 预测性能:R²从0.81(3次输入)升至0.94(5次输入),PCC从0.90升至0.97。
- CBCT4(放疗约第10天)预测:R²=0.91,PCC=0.95。
- 不良反应者(TVR≤10%)识别:敏感度77.7%、特异度73.6%、阴性预测值90.7%。
- 参数变化±20%以内模型稳定。
临床怎么用
- 可利用放疗早期(如CBCT 1-3或CBCT4)的肿瘤体积动态,通过PSI模型预测最终肿瘤体积退缩。
- 模型对识别不良反应者(TVR≤10%)具有较高阴性预测值,有助于早期识别可能获益于个体化放疗计划调整的患者。
局限性
- 样本量为71例,为单队列外部验证。
- 仅纳入接受根治性放疗(55 Gy/20次)的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Proliferation Saturation Index (PSI) model is a patient-specific mathematical model designed to simulate and predict tumor volume regression (TVR) during radiation therapy (RT) using early treatment response dynamics. This study validates the PSI model in an independent external cohort of patients with non-small cell lung cancer using previously derived model parameters. METHODS AND MATERIALS: In a cohort of 71 patients, treated with definitive RT alone (55 Gy/20#) tumor volume measurements were extracted from 6 cone beam computed tomography (CBCT) scans acquired on days 1, 2, and 3 and weekly thereafter. Model predictions of TVR at final CBCT (CBCT6) were made using tumor volume dynamics recorded from CBCT 1-3, CBCT 1-4, and CBCT 1-5. Agreement between predicted and actual volumes were assessed using the coefficient of determination (R2) and Pearson correlation coefficient (PCC). RESULTS: Model predictions showed strong agreement with measured volumes, improving with additional input data: R2 increased from 0.81 (3 inputs) to 0.94 (5 inputs), and PCC rose from 0.90 to 0.97. Prediction using data from approximately day 10 of RT (CBCT4) yielded R2 = 0.91 and PCC = 0.95. The model demonstrated strong performance in identifying poor responders (TVR ≤10%) with sensitivity of 77.7%, specificity of 73.6%, and a negative predictive value of 90.7%. Sensitivity analysis confirmed model stability with under ±20% parameter variation. CONCLUSIONS: This external validation confirms the PSI model's reproducibility and robustness in predicting TVR in patients with non-small cell lung cancer treated with definitive RT, supporting its integration into personalized RT planning strategies.
引用
- Barrett S, Zahid MU, McGarry CK, et al. External Validation of the Proliferation Saturation Index Model in Predicting Tumor Volume Regression in Patients With Non-Small Cell Lung Cancer Undergoing Radiation Therapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 41724248. doi:10.1016/j.ijrobp.2026.02.213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。